Chemical Formula: C41H64O14

Chemical Formula C41H64O14

Found 45 metabolite its formula value is C41H64O14

Digoxin

3-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-3-[(2R,4S,5S,6R)-5-[(2S,4S,5S,6R)-5-[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-4-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-4-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one

C41H64O14 (780.4295844)


Digoxin appears as clear to white crystals or white crystalline powder. Odorless. Used as a cardiotonic drug. (EPA, 1998) Digoxin is a cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small. It has a role as an epitope, an anti-arrhythmia drug, a cardiotonic drug and an EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor. It is a cardenolide glycoside and a steroid saponin. It is a conjugate acid of a digoxin(1-). Digoxin is one of the oldest cardiovascular medications used today. It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954. This drug originates from the foxglove plant, also known as the Digitalis plant, studied by William Withering, an English physician and botanist in the 1780s. Prior to this, a Welsh family, historically referred to as the Physicians of Myddvai, formulated drugs from this plant. They were one of the first to prescribe cardiac glycosides, according to ancient literature dating as early as the 1250s. Digoxin is a Cardiac Glycoside. Digoxin is a natural product found in Digitalis obscura, Digitalis parviflora, and other organisms with data available. Digoxin is a cardiac glycoside. Digoxin inhibits the sodium potassium adenosine triphosphatase (ATPase) pump, thereby increasing intracellular calcium and enhancing cardiac contractility. This agent also acts directly on the atrioventricular node to suppress conduction, thereby slowing conduction velocity. Apparently due to its effects on intracellular calcium concentrations, digoxin induces apoptosis of tumor cells via a pathway involving mitochondrial cytochrome c and caspases 8 and 3. (NCI04) Digoxin is a cardiac glycoside extracted from the foxglove plant, digitalis. It is widely used in the treatment of various heart conditions, namely atrial fibrillation, atrial flutter and congestive heart failure that cannot be controlled by other medication. Digoxin preparations are commonly marketed under the trade name Lanoxin. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666) Digoxin is a cardiotonic glycoside obtained mainly from Digitalis lanata; It consists of three sugars and the aglycone digoxigenin. Digoxin binds to a site on the extracellular aspect of the of the Na+/K+ ATPase pump in the membranes of heart cells (myocytes). This causes an increase in the level of sodium ions in the myocytes, which then leads to a rise in the level of calcium ions. The proposed mechanism is the following: inhibition of the Na+/K+ pump leads to increased Na+ levels, which in turn slows down the extrusion of Ca2+ via the Na+/Ca2+ exchange pump. Increased amounts of Ca2+ are then stored in the sarcoplasmic reticulum and released by each action potential, which is unchanged by digoxin. This is a different mechanism from that of catecholamines. Owing to its narrow therapeutic index (the margin between effectiveness and toxicity), side effects of digoxin are inevitable. Nausea, vomiting and GIT upset are common, especially in higher doses. Decreased conduction in the AV node can lead to AV blocks, increased intracellular Ca2+ causes a type of arrhythmia called bigeminy (coupled beats), eventually ventricular tachycardia or fibrillation. An often described but rarely seen side effect of digoxin is a disturbance of color vision (mos... Digoxin is a cardiac glycoside extracted from the foxglove plant, digitalis. It is widely used in the treatment of various heart conditions, namely atrial fibrillation, atrial flutter and congestive heart failure that cannot be controlled by other medication. Digoxin preparations are commonly marketed under the trade name Lanoxin. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666) -- Pubchem; Digoxin is a cardiotonic glycoside obtained mainly from Digitalis lanata; It consists of three sugars and the aglycone digoxigenin. Digoxin binds to a site on the extracellular aspect of the of the Na+/K+ ATPase pump in the membranes of heart cells (myocytes). This causes an increase in the level of sodium ions in the myocytes, which then leads to a rise in the level of calcium ions. The proposed mechanism is the following: inhibition of the Na+/K+ pump leads to increased Na+ levels, which in turn slows down the extrusion of Ca2+ via the Na+/Ca2+ exchange pump. Increased amounts of Ca2+ are then stored in the sarcoplasmic reticulum and released by each action potential, which is unchanged by digoxin. This is a different mechanism from that of catecholamines. -- Wikipedia; Owing to its narrow therapeutic index (the margin between effectiveness and toxicity), side effects of digoxin are inevitable. Nausea, vomiting and GIT upset are common, especially in higher doses. Decreased conduction in the AV node can lead to AV blocks, increased intracellular Ca2+ causes a type of arrhythmia called bigeminy (coupled beats), eventually ventricular tachycardia or fibrillation. An often described but rarely seen side effect of digoxin is a disturbance of color vision (mostly yellow and green color) called xanthopsia. Digoxin is a cardiac glycoside extracted from the foxglove plant, digitalis. It is widely used in the treatment of various heart conditions, namely atrial fibrillation, atrial flutter and congestive heart failure that cannot be controlled by other medication. Digoxin preparations are commonly marketed under the trade name Lanoxin. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666) -- Pubchem; A cardiotonic glycoside obtained mainly from Digitalis lanata; Digoxin binds to a site on the extracellular aspect of the of the Na+/K+ ATPase pump in the membranes of heart cells (myocytes). This causes an increase in the level of sodium ions in the myocytes, which then leads to a rise in the level of calcium ions. The proposed mechanism is the following: inhibition of the Na+/K+ pump leads to increased Na+ levels, which in turn slows down the extrusion of Ca2+ via the Na+/Ca2+ exchange pump. Increased amounts of Ca2+ are then stored in the sarcoplasmic reticulum and released by each action potential, which is unchanged by digoxin. This is a different mechanism from that of catecholamines. -- Wikipedia; Owing to its narrow therapeutic index (the margin between effectiveness and toxicity), side effects of digoxin are inevitable. Nausea, vomiting and GIT upset are common, especially in higher doses. Decreased conduction in the AV node can lead to AV blocks, increased intracellular Ca2+ causes a type of arrhythmia called bigeminy (coupled beats), eventually ventricular tachycardia or fibrillation. An often described but rarely seen side effect of digoxin is a disturbance of color vision (mostly yellow and green color) called xanthopsia. [HMDB] A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small. C - Cardiovascular system > C01 - Cardiac therapy > C01A - Cardiac glycosides > C01AA - Digitalis glycosides D020011 - Protective Agents > D002316 - Cardiotonic Agents > D004071 - Digitalis Glycosides D020011 - Protective Agents > D002316 - Cardiotonic Agents > D002301 - Cardiac Glycosides C274 - Antineoplastic Agent > C1931 - Antineoplastic Plant Product > C823 - Saponin C78274 - Agent Affecting Cardiovascular System > C78322 - Cardiotonic Agent D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents C1907 - Drug, Natural Product D004791 - Enzyme Inhibitors

   

Gitoxim

3-[(3S,5R,8R,9S,10S,13R,14S,16S,17R)-3-[(2R,4S,5S,6R)-5-[(2S,4S,5S,6R)-5-[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-14,16-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one

C41H64O14 (780.4295844)


Gitoxin is a cardenolide glycoside that is gitoxigenin in which the 3beta-hydroxy group has been glycosylated with tridigitoxose. It is functionally related to a gitoxigenin. Gitoxin is a natural product found in Digitalis obscura, Digitalis parviflora, and other organisms with data available. D020011 - Protective Agents > D002316 - Cardiotonic Agents > D004071 - Digitalis Glycosides D020011 - Protective Agents > D002316 - Cardiotonic Agents > D002301 - Cardiac Glycosides

   

Cynarasaponin F

6-[(8a-carboxy-10-hydroxy-4,4,6a,6b,11,12,14b-heptamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl)oxy]-3,4-dihydroxy-5-[(3,4,5-trihydroxyoxan-2-yl)oxy]oxane-2-carboxylic acid

C41H64O14 (780.4295844)


Constituent of Cynara cardunculus (cardoon). Cynarasaponin F is found in herbs and spices and green vegetables. Cynarasaponin F is found in green vegetables. Cynarasaponin F is a constituent of Cynara cardunculus (cardoon).

   

Cogoxin

4-(5-{[5-({5-[(4,5-dihydroxy-6-methyloxan-2-yl)oxy]-4-hydroxy-6-methyloxan-2-yl}oxy)-4-hydroxy-6-methyloxan-2-yl]oxy}-11,16-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-14-yl)-2,5-dihydrofuran-2-one

C41H64O14 (780.4295844)


D020011 - Protective Agents > D002316 - Cardiotonic Agents > D004071 - Digitalis Glycosides D020011 - Protective Agents > D002316 - Cardiotonic Agents > D002301 - Cardiac Glycosides D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents D004791 - Enzyme Inhibitors

   

Gitoxin

4-(5-{[5-({5-[(4,5-dihydroxy-6-methyloxan-2-yl)oxy]-4-hydroxy-6-methyloxan-2-yl}oxy)-4-hydroxy-6-methyloxan-2-yl]oxy}-11,13-dihydroxy-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadecan-14-yl)-2,5-dihydrofuran-2-one

C41H64O14 (780.4295844)


   

3-O-Allopyranosyl-(14)-oleandropyranosyl-11-O-isobutyryl-12-O-acetyltenacigenin B

[(3R,6R,7S,8S,9S,10S,11S,14S,16S)-6-acetyl-8-acetyloxy-14-[(2S,4R,5R,6R)-5-[(2S,3R,4R,5R,6R)-3,5-dihydroxy-4-methoxy-6-methyloxan-2-yl]oxy-4-methoxy-6-methyloxan-2-yl]oxy-7,11-dimethyl-2-oxapentacyclo[8.8.0.01,3.03,7.011,16]octadecan-9-yl] 2-methylpropanoate

C41H64O14 (780.4295844)


   
   
   
   
   

hederagenin 3-O-(O-beta-D-xylopyranosyl-(1-2)-beta-D-glucopyranoside)|hederagenin 3-O-

hederagenin 3-O-(O-beta-D-xylopyranosyl-(1-2)-beta-D-glucopyranoside)|hederagenin 3-O-

C41H64O14 (780.4295844)


   

28-O-(beta-D-xylopyranosyl-(1->2)-beta-D-glucopyranosyl)-3beta,19alpha-dihydroxyurs-23-oxo-12-en-28-oic acid|ilexpublesnin B

28-O-(beta-D-xylopyranosyl-(1->2)-beta-D-glucopyranosyl)-3beta,19alpha-dihydroxyurs-23-oxo-12-en-28-oic acid|ilexpublesnin B

C41H64O14 (780.4295844)


   
   

3-O-(2-beta-D-quinovopyranosyl-beta-D-xylopyranosyl)holothurinogenol

3-O-(2-beta-D-quinovopyranosyl-beta-D-xylopyranosyl)holothurinogenol

C41H64O14 (780.4295844)


   

(3beta)-3-(beta-D-glucopyranosyloxy)-12-oxopyroquinovic acid beta-D-glucopyranosyl ester|(3beta)-3-(beta-D-glucopyranosyloxy)-27-norurs-13-en-28-oic acid beta-D-glucopyranosyl ester|uncariaside A

(3beta)-3-(beta-D-glucopyranosyloxy)-12-oxopyroquinovic acid beta-D-glucopyranosyl ester|(3beta)-3-(beta-D-glucopyranosyloxy)-27-norurs-13-en-28-oic acid beta-D-glucopyranosyl ester|uncariaside A

C41H64O14 (780.4295844)


   

3beta,(24R),(28R)-trihydroxystigmasta-7,9(11)-dien-21,24-lactone-3-O-beta-D-galactopyranosyl-(1->4)-beta-D-glucopyranoside|vernocuminoside I

3beta,(24R),(28R)-trihydroxystigmasta-7,9(11)-dien-21,24-lactone-3-O-beta-D-galactopyranosyl-(1->4)-beta-D-glucopyranoside|vernocuminoside I

C41H64O14 (780.4295844)


   

3beta-[(O-beta-D-glucopyranosyl-(1->2)-alpha-L-arabinopyranosyl)oxy]-11alpha,12alpha-epoxy-13beta,23-dihydroxyoleanan-28-oic acid gamma-lactone

3beta-[(O-beta-D-glucopyranosyl-(1->2)-alpha-L-arabinopyranosyl)oxy]-11alpha,12alpha-epoxy-13beta,23-dihydroxyoleanan-28-oic acid gamma-lactone

C41H64O14 (780.4295844)


   

16-hydroxy-3beta-O-[beta-D-xylopyranosyl-(1->3)-beta-D-glucopyranosyloxyuronic acid]-5alpha,14beta-poriferast-16-ene-15,23-dione methyl ester|pandaroside H methyl ester

16-hydroxy-3beta-O-[beta-D-xylopyranosyl-(1->3)-beta-D-glucopyranosyloxyuronic acid]-5alpha,14beta-poriferast-16-ene-15,23-dione methyl ester|pandaroside H methyl ester

C41H64O14 (780.4295844)


   

3beta,28-di(beta-D-glucopyranosyloxy)-24-hydroxy-stigmasta-7(8),9(11)-dien-21,24-lactone|vernonioside S2

3beta,28-di(beta-D-glucopyranosyloxy)-24-hydroxy-stigmasta-7(8),9(11)-dien-21,24-lactone|vernonioside S2

C41H64O14 (780.4295844)


   

3-O-(beta-D-xylanopyranosyl)-28-O-(beta-D-glucopyranosyl)-3beta,19alpha-dihydroxyurs-23-oxo-12-en-28-oic acid|ilexpublesnin A

3-O-(beta-D-xylanopyranosyl)-28-O-(beta-D-glucopyranosyl)-3beta,19alpha-dihydroxyurs-23-oxo-12-en-28-oic acid|ilexpublesnin A

C41H64O14 (780.4295844)


   

Digoxin

Digoxin

C41H64O14 (780.4295844)


C - Cardiovascular system > C01 - Cardiac therapy > C01A - Cardiac glycosides > C01AA - Digitalis glycosides D020011 - Protective Agents > D002316 - Cardiotonic Agents > D004071 - Digitalis Glycosides D020011 - Protective Agents > D002316 - Cardiotonic Agents > D002301 - Cardiac Glycosides C274 - Antineoplastic Agent > C1931 - Antineoplastic Plant Product > C823 - Saponin C78274 - Agent Affecting Cardiovascular System > C78322 - Cardiotonic Agent D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents CONFIDENCE Reference Standard (Level 1); INTERNAL_ID 2 C1907 - Drug, Natural Product D004791 - Enzyme Inhibitors relative retention time with respect to 9-anthracene Carboxylic Acid is 1.276 relative retention time with respect to 9-anthracene Carboxylic Acid is 1.282 relative retention time with respect to 9-anthracene Carboxylic Acid is 1.275

   

ruscogenin 1-O-[O-alpha-L-rhamnopyranosyl-(1->2)-6-O-acetyl-beta-D-galactopyranoside]

ruscogenin 1-O-[O-alpha-L-rhamnopyranosyl-(1->2)-6-O-acetyl-beta-D-galactopyranoside]

C41H64O14 (780.4295844)


   

3-O-alpha-L-arabinopyranosyl-3beta,19alpha,23-trihydroxyursa-12,20(30)-dien-28-oic acid 28-O-beta-D-glucopyranosyl ester|randiasaponin I

3-O-alpha-L-arabinopyranosyl-3beta,19alpha,23-trihydroxyursa-12,20(30)-dien-28-oic acid 28-O-beta-D-glucopyranosyl ester|randiasaponin I

C41H64O14 (780.4295844)


   
   

3-O-alpha-L-arabinopyranosylgypsogenic acid 28-O-beta-D-glucopyranoside|chionaeoside C

3-O-alpha-L-arabinopyranosylgypsogenic acid 28-O-beta-D-glucopyranoside|chionaeoside C

C41H64O14 (780.4295844)


   

3-O-[alpha-L-arabinopyranosyl(1?2)]-beta-D-glucuronopyranosyl azukisapogenol

3-O-[alpha-L-arabinopyranosyl(1?2)]-beta-D-glucuronopyranosyl azukisapogenol

C41H64O14 (780.4295844)


   

4?-acetylypsilanogenin 3-beta?D-glucopyranoside

4?-acetylypsilanogenin 3-beta?D-glucopyranoside

C41H64O14 (780.4295844)


   
   

polygalasaponin XXVII

polygalasaponin XXVII

C41H64O14 (780.4295844)


   
   

quinovic acid 3beta-O-alpha-L-rhamnopyranosyl-(28-1)-beta-D-glucopyranosyl ester

quinovic acid 3beta-O-alpha-L-rhamnopyranosyl-(28-1)-beta-D-glucopyranosyl ester

C41H64O14 (780.4295844)


   
   

3-O-beta-D-glucopyranosyloxyuronic acid-(1->2)-beta-D-xylopyranosyl cyclamiretin A

3-O-beta-D-glucopyranosyloxyuronic acid-(1->2)-beta-D-xylopyranosyl cyclamiretin A

C41H64O14 (780.4295844)


   
   

16-hydroxy-3beta-O-[alpha-L-rhamnopyranosyl-(1->4)-beta-D-glucopyranosyloxyuronic acid]-5alpha,14beta-poriferast-16-ene-15,23-dione|pandaroside I

16-hydroxy-3beta-O-[alpha-L-rhamnopyranosyl-(1->4)-beta-D-glucopyranosyloxyuronic acid]-5alpha,14beta-poriferast-16-ene-15,23-dione|pandaroside I

C41H64O14 (780.4295844)


   
   
   

cynarasaponin F

6-[(8a-carboxy-10-hydroxy-4,4,6a,6b,11,12,14b-heptamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl)oxy]-3,4-dihydroxy-5-[(3,4,5-trihydroxyoxan-2-yl)oxy]oxane-2-carboxylic acid

C41H64O14 (780.4295844)


   

(1S,3R,4R,7R,9R,11R,15S,16R,17R,18S,19E,21E,25E,27E,29E,31E,33R,35S,36R,37S)-1,3,4,7,9,11,17,33,37-nonahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid

(1S,3R,4R,7R,9R,11R,15S,16R,17R,18S,19E,21E,25E,27E,29E,31E,33R,35S,36R,37S)-1,3,4,7,9,11,17,33,37-nonahydroxy-15,16,18-trimethyl-13-oxo-14,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,25,27,29,31-hexaene-36-carboxylic acid

C41H64O14 (780.4295844)


   

(2R,3S,4S,6S)-6-[(2R,3S,4S,6S)-6-[(2R,3S,4S,6R)-6-[[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-dihydroxy-17-(5-hydroxyfuran-3-yl)-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-4-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2-methyloxan-3-yl]oxy-2-methyloxane-3,4-diol

(2R,3S,4S,6S)-6-[(2R,3S,4S,6S)-6-[(2R,3S,4S,6R)-6-[[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-12,14-dihydroxy-17-(5-hydroxyfuran-3-yl)-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-yl]oxy]-4-hydroxy-2-methyloxan-3-yl]oxy-4-hydroxy-2-methyloxan-3-yl]oxy-2-methyloxane-3,4-diol

C41H64O14 (780.4295844)


   
   

3-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-3-[(2R,4S,5S,6R)-5-[(4R,5S,6R)-5-[(4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one

3-[(3S,5R,8R,9S,10S,12R,13S,14S,17R)-3-[(2R,4S,5S,6R)-5-[(4R,5S,6R)-5-[(4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-12,14-dihydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one

C41H64O14 (780.4295844)